Samsung Bioepis Begins First Phase 1 Clinical Trial for ADC New Drug

Samsung Bioepis has initiated Phase 1 clinical trials for its antibody-drug conjugate (ADC) new drug candidate, SBE303.

A view of the Samsung Bioepis building in Yeonsu-gu, Incheon. Samsung Bioepis

According to ClinicalTrials.gov, the clinical trial information disclosure site of the U.S. National Institutes of Health (NIH), the Phase 1 trial of SBE303 began last month and will continue until July 2030, targeting 149 patients with advanced solid tumors worldwide.

This clinical trial will evaluate the safety, tolerability, and efficacy of SBE303.

SBE303 is Samsung Bioepis's first new drug and targets Nectin-4, which is observed in tumor cells.

This year, the Phase 1 clinical trial plan for this drug was also approved in Korea.

This content was produced with the assistance of AI translation services.